FB Nasdaq FB Facebook

DoCoMo Reports In-Line Fiscal 4Q, but Provides Lower Guidance; Under Review

NTT DoCoMo DCM reported fiscal year-end results that were generally in line with our expectations, but margin guidance for this year was lower than we anticipated. We have put our fair value estimate under review as we revise our model projections. There is no change to our economic moat rating. Revenue grew 5.4% year over…

Read More

Biotech Stock To Buy: InterMune(ITMN) Gets Breakthrough Therapy Designation

InterMune, Inc. (ITMN ) received breakthrough therapy designation for its primary product, Esbriet (pirfenidone), from the FDA. InterMune is looking to get Esbriet approved in the U.S. for the treatment of adults suffering from idiopathic pulmonary fibrosis (IPF). Breakthrough therapy designation is a status provided to candidates that show superiority over existing therapies for the…

Read More